A Phase III Randomized Open-Label Study of Single Agent SHR-1210 vs Investigator's Choice Standard Therapy in Subjects With Advanced/Metastatic Esophageal Cancer
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs INCSHR 1210 (Primary) ; Docetaxel; Irinotecan
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 25 May 2017 Status changed from not yet recruiting to recruiting.
- 07 Apr 2017 New trial record